Provided By GlobeNewswire
Last update: Nov 15, 2024
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial
Overall, in Cohort A1, 25% of patients achieved functional cure
Read more at globenewswire.comNASDAQ:ABUS (11/19/2025, 2:58:29 PM)
4.27
-0.18 (-4.04%)
Find more stocks in the Stock Screener


